Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2

Oncotarget

Volumn 6, Issue 29, 2015, Pages 28389-28400

  Ghilardi, Carmen ^a   Silini, Antonietta ^a   Figini, Sara ^a   Anastasia, Alessia ^a   Lupi, Monica ^a   Fruscio, Robert ^b   Giavazzi, Raffaella ^a   Bani, MariaRosa ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

Cancer microenvironment; Endothelial cells; Serine protease 3 (PRSS3) trypsinogen 4; Tissue factor pathway inhibitor 2 (TFPI 2); Tumor angiogenesis

Indexed keywords

EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; PLACENTA PROTEIN 5; SERINE PROTEASE 1; SERINE PROTEASE 2; SERINE PROTEASE 3; SMALL INTERFERING RNA; TRYPSINOGEN; TRYPSINOGEN 4; UNCLASSIFIED DRUG; VASCULOTROPIN A; GLYCOPROTEIN; PRSS3 PROTEIN, HUMAN; TISSUE-FACTOR-PATHWAY INHIBITOR 2; TRYPSIN;

ARTICLE; CANCER TISSUE; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UPREGULATION; CELL CULTURE; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; VASCULARIZATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIAL CELLS; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; NEOPLASMS; PROTEOLYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRYPSIN; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84944462982     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4949     Document Type: Article

References (29)

1. van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol. 2006; 26:716-728.
2. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer. 2007; 7:800-808.
3. Diederichs S, Bulk E, Steffen B, Ji P, Tickenbrock L, Lang K, Zanker KS, Metzger R, Schneider PM, Gerke V, Thomas M, Berdel WE, Serve H, et al. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res. 2004; 64:5564-5569.
4. Hockla A, Miller E, Salameh MA, Copland JA, Radisky DC, Radisky ES. PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer. Mol Cancer Res. 2012; 10:1555-1566.
5. Jiang G, Cao F, Ren G, Gao D, Bhakta V, Zhang Y, Cao H, Dong Z, Zang W, Zhang S, Wong HH, Hiley C, Crnogorac-Jurcevic T, et al. PRSS3 promotes tumour growth and metastasis of human pancreatic cancer. Gut. 2010; 59:1535-1544.
6. Salameh MA, Soares AS, Navaneetham D, Sinha D, Walsh PN, Radisky ES. Determinants of affinity and proteolytic stability in interactions of Kunitz family protease inhibitors with mesotrypsin. J Biol Chem. 2010; 285:36884-36896.
7. Sahin-Toth M. Human mesotrypsin defies natural trypsin inhibitors: from passive resistance to active destruction. Protein Pept Lett. 2005; 12:457-464.
8. Wiegand U, Corbach S, Minn A, Kang J, Muller-Hill B. Cloning of the cDNA encoding human brain trypsinogen and characterization of its product. Gene. 1993; 136:167-175.
9. Toth J, Siklodi E, Medveczky P, Gallatz K, Nemeth P, Szilagyi L, Graf L, Palkovits M. Regional distribution of human trypsinogen 4 in human brain at mRNA and protein level. Neurochem Res. 2007; 32:1423-1433.
10. Cottrell GS, Amadesi S, Grady EF, Bunnett NW. Trypsin IV, a novel agonist of protease-activated receptors 2 and 4. J Biol Chem. 2004; 279:13532-13539.
11. Salameh MA, Radisky ES. Biochemical and structural insights into mesotrypsin: an unusual human trypsin. Int J Biochem Mol Biol. 2013; 4:129-139.
12. Ghilardi C, Chiorino G, Dossi R, Nagy Z, Giavazzi R, Bani M. Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics. 2008; 9:201.
13. Roy R, Zhang B, Moses MA. Making the cut: proteasemediated regulation of angiogenesis. Exp Cell Res. 2006; 312:608-622.
14. Nyberg P, Ylipalosaari M, Sorsa T, Salo T. Trypsins and their role in carcinoma growth. Exp Cell Res. 2006; 312:1219-1228.
15. Koshikawa N, Nagashima Y, Miyagi Y, Mizushima H, Yanoma S, Yasumitsu H, Miyazaki K. Expression of trypsin in vascular endothelial cells. FEBS Lett. 1997; 409:442-448.
16. Ivanciu L, Gerard RD, Tang H, Lupu F, Lupu C. Adenovirus-mediated expression of tissue factor pathway inhibitor-2 inhibits endothelial cell migration and angiogenesis. Arterioscler Thromb Vasc Biol. 2007; 27:310-316.
17. Iino M, Foster DC, Kisiel W. Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Arterioscler Thromb Vasc Biol. 1998; 18:40-46.
18. Nemeth AL, Medveczky P, Toth J, Siklodi E, Schlett K, Patthy A, Palkovits M, Ovadi J, Tokesi N, Nemeth P, Szilagyi L, Graf L. Unconventional translation initiation of human trypsinogen 4 at a CUG codon with an N-terminal leucine. A possible means to regulate gene expression. FEBS J. 2007; 274:1610-1620.
19. Yanamandra N, Kondraganti S, Gondi CS, Gujrati M, Olivero WC, Dinh DH, Rao JS. Recombinant adenoassociated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int J Cancer. 2005; 115:998-1005.
20. Xu Z, Maiti D, Kisiel W, Duh EJ. Tissue factor pathway inhibitor-2 is upregulated by vascular endothelial growth factor and suppresses growth factor-induced proliferation of endothelial cells. Arterioscler Thromb Vasc Biol. 2006; 26:2819-2825.
21. Sierko E, Wojtukiewicz MZ, Kisiel W. The role of tissue factor pathway inhibitor-2 in cancer biology. Semin Thromb Hemost. 2007; 33:653-659.
22. Nobeyama Y, Okochi-Takada E, Furuta J, Miyagi Y, Kikuchi K, Yamamoto A, Nakanishi Y, Nakagawa H, Ushijima T. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer. 2007; 121:301-307.
23. Wang S, Xiao X, Zhou X, Huang T, Du C, Yu N, Mo Y, Lin L, Zhang J, Ma N, Murata M, Huang G, Zhang Z. TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer. 2010; 10:617.
24. Hockla A, Radisky DC, Radisky ES. Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. Breast Cancer Res Treat. 2010; 124:27-38.
25. Sidiropoulos KG, White NM, Bui A, Ding Q, Boulos P, Pampalakis G, Khella H, Samuel JN, Sotiropoulou G, Yousef GM. Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer. Oncoscience. 2014; 1:709-724.
26. Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis. Circ Res. 2007; 100:782-794.
27. Silini A, Ghilardi C, Figini S, Sangalli F, Fruscio R, Dahse R, Pedley RB, Giavazzi R, Bani M. Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. Cell Mol Life Sci. 2012; 69:1167-1178.
28. Rodriguez LG, Wu X, Guan JL. Wound-healing assay. Methods Mol Biol. 2005; 294:23-29.
29. Margosio B, Marchetti D, Vergani V, Giavazzi R, Rusnati M, Presta M, Taraboletti G. Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood. 2003; 102:4399-4406.